Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
|Articles|January 27, 2022
Pharmacy Clinical Pearl of the Day: Gonorrhea
Author(s)Saro Arakelians, PharmD
Symptoms of gonorrhea include painful urination, pain or swelling in the affected area, vaginal bleeding, and abdominal pain.
Advertisement
Clinical Pearl of the Day: Gonorrhea
Gonorrhea is an infection caused by a sexually transmitted bacterium that infects both males and females.
Insight:
- Gonorrhea most often affects the urethra, rectum, or throat. In females, gonorrhea can also infect the cervix.
- Gonorrhea is commonly spread during vaginal, oral, or anal sex; however, babies of infected mothers can subsequently be infected during childbirth. In babies, gonorrhea most commonly affects the eyes.
- Abstaining from sex, using a condom during sex, and being in a mutually monogamous relationship are the best ways to prevent sexually transmitted infections.
- Symptoms include painful urination, pain or swelling in the affected area, vaginal bleeding, and abdominal pain.
- Diagnosis includes urine test and swabs of the area.
- Treatment includes antibiotics such as ceftriaxone and zithromax, as well as gemifloxacin.
Sources:
Advertisement
Related to this article
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5